Copeptin After Arginine Infusion in Polyuria-Polydipsia Syndrome

Healthy Clinical Trial

Official title:

Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study''

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01879137
• Other study ID #: CARGO 2013
• Status: Completed
• Phase: N/A
• First received: June 12, 2013
• Last updated: July 10, 2017
• Start date: June 2013
• Est. completion date: May 2017

Study information

• Verified date: July 2017
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

the purpose of the study is to investigate whether arginine infusion is a new tool to differentiate patients with diabetes insipidus, primary polydipsia and healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age over 18 years

2. No medication except hormonal contraception

Exclusion Criteria:

1. Evidence of any acute illness

2. Subjects refusing or unable to give written informed consent

3. Pregnancy

4. Any evidence of disordered drinking habits and diuresis

Related Conditions & MeSH terms

• Diabetes Insipidus
• Healthy
• Polydipsia
• Polyuria
• Polyuria-polydipsia Syndrome
• Syndrome

Locations

Country	Name	City	State
Switzerland	University Hospital Basel	Basel	Basel-Stadt

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome.		up to 120 minutes after the Arginine infusion.